There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
<p class="first" id="d16701111e115">Two anti-CD19 chimeric antigen receptor T-cell
(CAR-T) therapies are approved for
diffuse large B-cell lymphoma, axicabtagene ciloleucel (axi-cel) and tisagenlecleucel;
each costs $373,000. We evaluated their cost effectiveness.
</p>